Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 18/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumagillin SCHEMBL13819097 | 1.00 | METAP2 (1.00) | METAP2ABCB11LMNAMEN1ALDH1A1 | |
| Fumagillin SCHEMBL18517986 | 1.00 | METAP2 (1.00) | METAP2ABCB11LMNAMEN1ALDH1A1 | |
| Fumagillin SCHEMBL17959149 | 1.00 | METAP2 (1.00) | METAP2ABCB11LMNAMEN1ALDH1A1 | |
| Fumagillin SCHEMBL12526078 | 1.00 | METAP2 (1.00) | METAP2ABCB11LMNAMEN1ALDH1A1 | |
| Fumagillin SCHEMBL18517793 | 1.00 | METAP2 (1.00) | METAP2ABCB11LMNAMEN1ALDH1A1 | |
| Fumagillin SCHEMBL15263951 | 1.00 | METAP2 (1.00) | METAP2ABCB11LMNAMEN1ALDH1A1 | |
| Fumagillin SCHEMBL6953272 | 1.00 | METAP2 (1.00) | METAP2ABCB11LMNAMEN1ALDH1A1 | |
| Fumagillin SCHEMBL13304359 | 1.00 | METAP2 (1.00) | METAP2ABCB11LMNAMEN1ALDH1A1 | |
| Fumagillin SCHEMBL15745869 | 1.00 | METAP2 (1.00) | METAP2ABCB11LMNAMEN1ALDH1A1 | |
| Fumagillin SCHEMBL18517985 | 1.00 | METAP2 (1.00) | METAP2ABCB11LMNAMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 10770 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| WO-2026043908-A1 | COMPOSITIONS AND METHODS TO IMPROVE SEQUESTRATION OF MYCOTOXINS AND THEIR USE IN DETOXIFICATION OF ANIMAL FEED AND ANIMAL PRODUCTION SYSTEMS | ALLTECH, INC. (US) | 2026-02-26 | — | — | WO | claimed |
| US-12465623-B2 | Use of parasites and extracellular vesicles obtained from parasites in cancer treatment | YEDITEPE UNIVERSITESI (TR) | 2025-11-11 | — | — | US | claimed |
| US-20250325717-A1 | ANTI-NUCLEOPHOSMIN 1 ANTIBODY AND ANTIBODY CONJUGATE COMBINATION THERAPIES | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2025-10-23 | — | — | US | claimed |
| EP-4633617-A1 | USE OF BORON FOR THE TREATMENT OF LEISHMANIASIS DISEASE | Yeditepe Universitesi (TR) | 2025-10-22 | — | — | EP | claimed |
| EP-4633643-A1 | USE OF BORON FOR THE TREATMENT OF LEISHMANIASIS DISEASE OF NEURONAL ORIGIN | Yeditepe Universitesi (TR) | 2025-10-22 | — | — | EP | claimed |
| US-20250313647-A1 | MUTANT AND MISLOCALIZED CELL SURFACE NUCLEOPHOSMIN 1 AS A DIAGNOSTIC AND THERAPEUTIC TARGET OF HUMAN DISEASE | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2025-10-09 | — | — | US | claimed |
| US-20250295692-A1 | ISOLATION OF ANTI-INFLAMMATORY NEUTROPHIL OR MONOCYTE SUBSET AND USE IN TREATING CARDIOVASCULAR DISEASES | VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. | 2025-09-25 | — | — | US | claimed |
| EP-3965808-B1 | USE OF PARASITES AND EXTRACELLULAR VESICLES OBTAINED FROM PARASITES IN CANCER TREATMENT | UNIV YEDITEPE (TR) | 2025-09-03 | — | — | EP | claimed |
| EP-4580677-A2 | SARS-COV2 ANTIBODIES AND USES THEREOF | Invivyd, Inc. (US) | 2025-07-09 | — | — | EP | claimed |
| EP-0325199-B1 | Fumagillin as angiostatic agent | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1993-10-27 | — | — | EP | claimed |
| US-5227372-A | METHOD FOR RETAINING OPHTHALMOLOGICAL AGENTS IN OCULAR TISSUES | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 1993-07-13 | — | — | US | claimed |
| EP-0541716-A1 | NOVEL METHODS AND COMPOSITIONS FOR TREATMENT OF ANGIOGENIC DISEASES | REPLIGEN CORPORATION (US) | 1993-05-19 | — | — | EP | claimed |
| US-5196406-A | Antitumor, antiinflammatory | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-03-23 | — | — | US | claimed |
| US-5135919-A | Using fumagillin | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 1992-08-04 | — | — | US | claimed |
| US-5135920-A | Administering dextran sulfate, beta-1,3-glucan sulfate or salts; steroids, fumagillins; treating vision defects, arthritis; diseases caused by abnormally accelerated angiogenesis | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1992-08-04 | — | — | US | claimed |
| WO-1992002240-A2 | NOVEL METHODS AND COMPOSITIONS FOR TREATMENT OF ANGIOGENIC DISEASES | REPLIGEN CORPORATION (US) | 1992-02-20 | — | — | WO | claimed |
| EP-0461427-A2 | Cyclodextrin complex | Takeda Chemical Industries, Ltd. (JP) | 1991-12-18 | — | — | EP | claimed |
| EP-0447351-A1 | Medicament for retaining ophthalmological agents in ocular tissues and method for its production | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 1991-09-18 | — | — | EP | claimed |
| EP-0325199-A2 | Fumagillin as angiostatic agent | Takeda Chemical Industries, Ltd. (JP) | 1989-07-26 | — | — | EP | claimed |